Avanir Pharmaceuticals has licensed North American rights to OptiNose’s Breath Powered™ intranasal delivery system containing low-dose sumatriptan powder for the treatment of acute migraine. The two companies will collaborate to complete the remaining activities needed to support regulatory submission of the drug-device combination, now known as AVP-825, with NDA filing expected by early 2014. If approved, AVP-825 will diversify Avanir’s CNS product portfolio beyond Nuedexta® (dextromethorphan plus quinidine sulphate), which is indicated for the treatment of pseudobulbar affect.